CNS Drugs

, Volume 25, Issue 5, pp 371–382 | Cite as

Pharmacotherapy for Smoking Cessation

Current Advances and Research Topics
Review Article

Abstract

Promoting smoking cessation is among the key medical interventions aimed at reducing worldwide morbidity and mortality in this century. Both behavioural counselling and pharmacotherapy have been shown to significantly increase long-term abstinence rates, and combining the two treatment modalities is recommended. This article provides an update on pharmacotherapy for smoking cessation in the general population.

Current first-line agents used to support quit attempts are nicotine replacement therapy (NRT), bupropion and varenicline. Research suggests that abstinence rates can be increased by combining different forms of NRT or simultaneously administering NRT and non-nicotine medications. New treatments targeting the nicotinic acetylcholine receptor as well as other pathophysiological pathways involved in nicotine addiction are being developed, with nicotine vaccines now being tested in phase III clinical trials.

Among the numerous research topics currently addressed, pharmacogenetics and tailoring therapy to specific groups of smokers look most promising. However, substantial progress is unlikely to be made unless social gradients impeding effective treatment of all smokers are overcome. In addition, public smoking bans and reimbursement of medication costs are crucial in reducing the future burden of disease caused by smoking on a global level.

Notes

Acknowledgements

No sources of funding were received to prepare this review.

T. Raupach has been reimbursed for attendance and lecturing at several Pfizer symposia on smoking cessation from 2006 through 2010, and has received a grant from Pfizer for conducting a trial, as well as honoraria from GlaxoSmithKline, Astra Zeneca and Novartis for presentations. C.P. van Schayck has received funding for research proposals from GlaxoSmithKline and Pfizer, as well as reimbursement for lecturing and being on an advisory board for Pfizer.

References

  1. 1.
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006 Nov; 3(11): e442PubMedCrossRefGoogle Scholar
  2. 2.
    Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005 Feb 15; 142(4): 233–9PubMedGoogle Scholar
  3. 3.
    Fiore MC, Jaén CR, Baker TB. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, 2008 MayGoogle Scholar
  4. 4.
    Stead LF, Bergson G, Lancaster T. Physician advice forsmoking cessation. Cochrane Database Syst Rev 2008; (2): CD000165Google Scholar
  5. 5.
    Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med 2008 Apr; 121(4 Suppl. 1): S20–31PubMedCrossRefGoogle Scholar
  6. 6.
    Rose JE, Herskovic JE, Behm FM, et al. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. Nicotine Tob Res 2009 Sep; 11(9): 1067–75PubMedCrossRefGoogle Scholar
  7. 7.
    Etter JF, Huguelet P, Perneger TV, et al. Nicotine gum treatment before smoking cessation: a randomized trial. Arch Intern Med 2009 Jun 8; 169(11): 1028–34PubMedCrossRefGoogle Scholar
  8. 8.
    Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002 Sep 11; 288(10): 1260–4PubMedCrossRefGoogle Scholar
  9. 9.
    West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the “real world”? Findings from a prospective multinational cohort study. Thorax 2007 Nov; 62(11): 998–1002PubMedCrossRefGoogle Scholar
  10. 10.
    Burns EK, Levinson AH. Discontinuation of nicotine replacement therapy among smoking-cessation attempters. Am J Prev Med 2008 Mar; 34(3): 212–5PubMedCrossRefGoogle Scholar
  11. 11.
    Wiggers LC, Smets EM, Oort FJ, et al. Adherence to nicotine replacement patch therapy in cardiovascular patients. Int J Behav Med 2006; 13(1): 79–88PubMedCrossRefGoogle Scholar
  12. 12.
    Shiffman S, Sweeney CT, Ferguson SG, et al. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clin Ther 2008 Oct; 30(10): 1852–8PubMedCrossRefGoogle Scholar
  13. 13.
    Raupach T, Shahab L, Eimer S, et al. Increasing the use of nicotine replacement therapy by a simple intervention: an exploratory trial. Subst Use Misuse 2010 Feb; 45(3): 403–13PubMedCrossRefGoogle Scholar
  14. 14.
    Schneider NG, Olmstead RE, Nides M, et al. Comparative testing of 5 nicotine systems: initial use and preferences. Am J Health Behav 2004 Jan–Feb; 28(1): 72–86PubMedCrossRefGoogle Scholar
  15. 15.
    Vogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res 2008 Aug; 10(8): 1405–13PubMedCrossRefGoogle Scholar
  16. 16.
    Kaper J, Wagena EJ, Willemsen MC, et al. A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. Addiction 2006 Nov; 101(11): 1656–61PubMedCrossRefGoogle Scholar
  17. 17.
    Kaper J, Wagena EJ, van Schayck CP, et al. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment. Pharmacoeconomics 2006; 24(5): 453–64PubMedCrossRefGoogle Scholar
  18. 18.
    Kaper J, Wagena EJ, Willemsen MC, et al. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005 Jul; 100(7): 1012–20PubMedCrossRefGoogle Scholar
  19. 19.
    Liu F. Effect of Medicaid coverage of tobacco-dependence treatments on smoking cessation. Int J Environ Res Public Health 2009 Dec; 6(12): 3143–55PubMedCrossRefGoogle Scholar
  20. 20.
    Petersen R, Garrett JM, Melvin CL, et al. Medicaid reimbursement for prenatal smoking intervention influences quitting and cessation. Tob Control 2006 Feb; 15(1): 30–4PubMedCrossRefGoogle Scholar
  21. 21.
    Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340: b5569PubMedCrossRefGoogle Scholar
  22. 22.
    Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002 Jun; 2(6): 455–63PubMedCrossRefGoogle Scholar
  23. 23.
    Yamanaka H, Nakajima M, Fukami T, et al. CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 2005 Dec; 33(12): 1811–8PubMedGoogle Scholar
  24. 24.
    Heusch WL, Maneckjee R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis 1998 Apr; 19(4): 551–6PubMedCrossRefGoogle Scholar
  25. 25.
    Davis R, Rizwani W, Banerjee S, et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One 2009; 4(10): e7524PubMedCrossRefGoogle Scholar
  26. 26.
    Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res 2009 Sep; 11(9): 1076–82PubMedCrossRefGoogle Scholar
  27. 27.
    Arias HR. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol 2009 Nov; 41(11): 2098–108PubMedCrossRefGoogle Scholar
  28. 28.
    Paterson NE. Behavioural and pharmacological mechanisms of bupropion’s anti-smoking effects: recent preclinical and clinical insights. Eur J Pharmacol 2009 Jan 28; 603(1–3): 1–11PubMedCrossRefGoogle Scholar
  29. 29.
    Van Schayck CP, Kaper J, Wagena EJ, et al. The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction 2009 Dec; 104(12): 2110–7PubMedCrossRefGoogle Scholar
  30. 30.
    Levine MD, Perkins KA, Kalarchian MA, et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med 2010 Mar 22; 170(6): 543–50PubMedCrossRefGoogle Scholar
  31. 31.
    Wilcox CS, Oskooilar N, Erickson JS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 2010 Mar; 35(3): 229–34PubMedCrossRefGoogle Scholar
  32. 32.
    Parsons AC, Shraim M, Inglis J, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2009; (1): CD006219Google Scholar
  33. 33.
    Fucito LM, Toll BA, Salovey P, et al. Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment. Psychol Addict Behav 2009 Jun; 23(2): 373–9PubMedCrossRefGoogle Scholar
  34. 34.
    Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008; (3): CD006103Google Scholar
  35. 35.
    West R, Baker CL, Cappelleri JC, et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 2008 Apr; 197(3): 371–7CrossRefGoogle Scholar
  36. 36.
    Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010 Jan 19; 121(2): 221–9PubMedCrossRefGoogle Scholar
  37. 37.
    Bolin K, Wilson K, Benhaddi H, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries. Eur J Public Health 2009 Dec; 19(6): 650–4PubMedCrossRefGoogle Scholar
  38. 38.
    Keiding H. Cost-effectiveness of varenicline for smoking cessation. Expert Rev Pharmacoecon Outcomes Res 2009 Jun; 9(3): 215–21PubMedCrossRefGoogle Scholar
  39. 39.
    Blak BT, Wilson K, Metcalfe M, et al. Evaluation of varenicline as an aid to smoking cessation in UK general practice: a THIN database study. Curr Med Res Opin 2010 Apr; 26(4): 861–70PubMedCrossRefGoogle Scholar
  40. 40.
    Hajek P, Tonnesen P, Arteaga C, et al. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction 2009 Sep; 104(9): 1597–602PubMedCrossRefGoogle Scholar
  41. 41.
    Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal ehaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805PubMedCrossRefGoogle Scholar
  42. 42.
    Stapleton J. Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link? Addiction 2009 May; 104(5): 864–5PubMedCrossRefGoogle Scholar
  43. 43.
    Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010 Apr 1; 33(4): 289–301PubMedCrossRefGoogle Scholar
  44. 44.
    Henningfield JE, Shiffman S, Ferguson SG, et al. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther 2009 Jul; 123(1): 1–16PubMedCrossRefGoogle Scholar
  45. 45.
    Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007 Sep; 6(9): 746–62PubMedCrossRefGoogle Scholar
  46. 46.
    Sood A, Ebbert JO, Wyatt KD, et al. Gabapentin for smoking cessation. Nicotine Tob Res 2010 Mar; 12(3): 300–4PubMedCrossRefGoogle Scholar
  47. 47.
    Weinberger AH, Reutenauer EL, Jatlow PI, et al. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend 2010 Mar 1; 107(2–3): 188–95PubMedCrossRefGoogle Scholar
  48. 48.
    Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009 Jul 1; 103(1–2): 30–6PubMedCrossRefGoogle Scholar
  49. 49.
    Rohsenow DJ, Tidey JW, Miranda R, et al. Olanzapinereduces urge to smoke and nicotine withdrawal symptoms in community smokers. Exp Clin Psychopharmacol 2008 Jun; 16(3): 215–22PubMedCrossRefGoogle Scholar
  50. 50.
    Balfour DJ. Neural mechanisms underlying nicotine dependence. Addiction 1994 Nov; 89(11): 1419–23PubMedCrossRefGoogle Scholar
  51. 51.
    Dwoskin LP, Smith AM, Wooters TE, et al. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol 2009 Oct 1; 78(7): 732–43PubMedCrossRefGoogle Scholar
  52. 52.
    Grady SR, Murphy KL, Cao J, et al. Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. J Pharmacol Exp Ther 2002; 301(2): 651–60PubMedCrossRefGoogle Scholar
  53. 53.
    Zatonski W, Cedzynska M, Tutka P, et al. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control 2006 Dec; 15(6): 481–4PubMedCrossRefGoogle Scholar
  54. 54.
    Zwart R, Carbone AL, Moroni M, et al. Sazetidine-A is apotent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Mol Pharmacol 2008 Jun; 73(6): 1838–43PubMedCrossRefGoogle Scholar
  55. 55.
    Rose JE, Behm FM, Westman EC, et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994 Jul; 56(1): 86–99PubMedCrossRefGoogle Scholar
  56. 56.
    Yoshimura RF, Hogenkamp DJ, Li WY, et al. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. J Pharmacol Exp Ther 2007 Dec; 323(3): 907–15PubMedCrossRefGoogle Scholar
  57. 57.
    Neugebauer NM, Zhang Z, Crooks PA, et al. Effect of a novel nicotinic receptor antagonist, N,N′-dodecane-1, 12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology (Berl) 2006 Mar; 184(3–4): 426–34CrossRefGoogle Scholar
  58. 58.
    Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008; 68(8): 1067–88PubMedCrossRefGoogle Scholar
  59. 59.
    Liechti ME, Markou A. Role of the glutamatergic system in nicotine dependence: implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs 2008; 22(9): 705–24PubMedCrossRefGoogle Scholar
  60. 60.
    Le Foll B, Forget B, Aubin HJ, et al. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 2008 Jun; 13(2): 239–52PubMedCrossRefGoogle Scholar
  61. 61.
    Rigotti NA, Gonzales D, Dale LC, et al. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 2009 Feb; 104(2): 266–76PubMedCrossRefGoogle Scholar
  62. 62.
    Stapleton JA. Trial comes too late as psychiatric side effects end hope for rimonabant. Addiction 2009 Feb; 104(2): 277–8PubMedCrossRefGoogle Scholar
  63. 63.
    Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009 Apr; 5(4): 200–5PubMedCrossRefGoogle Scholar
  64. 64.
    de Villiers SH, Lindblom N, Kalayanov G, et al. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine 2010 Mar 2; 28(10): 2161–8PubMedCrossRefGoogle Scholar
  65. 65.
    Leader AE, Lerman C, Cappella JN. Nicotine vaccines: will smokers take a shot at quitting? Nicotine Tob Res 2010 Apr; 12(4): 390–7PubMedCrossRefGoogle Scholar
  66. 66.
    Wagena EJ, de Vos A, Horwith G, et al. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res 2008 Jan; 10(1): 213–8PubMedCrossRefGoogle Scholar
  67. 67.
    Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008; 3(6): e2547PubMedCrossRefGoogle Scholar
  68. 68.
    Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? Drugs 2010 Apr 16; 70(6): 643–50PubMedCrossRefGoogle Scholar
  69. 69.
    Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 1999 Jan 30; 318 (7179ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year. Nicotine Tob Res 2009 Sep; 11(9): 1114–21Google Scholar
  70. 70.
    Bohadana A, Nilsson F, Rasmussen T, et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000 Nov 13; 160(20): 3128–34PubMedCrossRefGoogle Scholar
  71. 71.
    Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD000146Google Scholar
  72. 72.
    Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009 Nov; 66(11): 1253–62PubMedCrossRefGoogle Scholar
  73. 73.
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999 Mar 4; 340(9): 685–91PubMedCrossRefGoogle Scholar
  74. 74.
    Smith SS, McCarthy DE, Japuntich SJ, et al. Comparativeeffectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009 Dec 14; 169(22): 2148–55PubMedCrossRefGoogle Scholar
  75. 75.
    Croghan IT, Hurt RD, Dakhil SR, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc 2007 Feb; 82(2): 186–95PubMedGoogle Scholar
  76. 76.
    Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 2009 Apr 7; 150(7): 447–54PubMedGoogle Scholar
  77. 77.
    Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004 Nov 8; 164(20): 2229–33PubMedCrossRefGoogle Scholar
  78. 78.
    Aveyard P, Johnson C, Fillingham S, et al. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 2008 May 31; 336(7655): 1223–7PubMedCrossRefGoogle Scholar
  79. 79.
    Ebbert JO, Burke MV, Hays JT, et al. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009 May; 11(5): 572–6PubMedCrossRefGoogle Scholar
  80. 80.
    Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009 Mar; 11(3): 234–9PubMedCrossRefGoogle Scholar
  81. 81.
    Kortmann GL, Dobler CJ, Bizarro L, et al. Pharmacogenetics of smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2010 Jan 5; 153B(1): 17–28PubMedGoogle Scholar
  82. 82.
    Malaiyandi V, Lerman C, Benowitz NL, et al. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006 Apr; 11(4): 400–9PubMedCrossRefGoogle Scholar
  83. 83.
    Schnoll RA, Patterson F, Wileyto EP, et al. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009 Mar; 92(1): 6–11PubMedCrossRefGoogle Scholar
  84. 84.
    Lerman C, Jepson C, Wileyto EP, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther 2010 May; 87(5): 553–7PubMedCrossRefGoogle Scholar
  85. 85.
    Patterson F, Schnoll RA, Wileyto EP, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008 Sep; 84(3): 320–5PubMedCrossRefGoogle Scholar
  86. 86.
    Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 2009; 23(3): 252–61PubMedCrossRefGoogle Scholar
  87. 87.
    David SP, Munafo MR, Murphy MF, et al. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 2008 Apr; 8(2): 122–8PubMedCrossRefGoogle Scholar
  88. 88.
    Perkins KA, Lerman C, Fonte CA, et al. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 2010 Jul; 88(1): 109–14PubMedCrossRefGoogle Scholar
  89. 89.
    Perkins KA, Lerman C, Stitzer M, et al. Development of procedures for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 2008 Aug; 84(2): 216–21PubMedCrossRefGoogle Scholar
  90. 90.
    Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009; 338: b1024PubMedCrossRefGoogle Scholar
  91. 91.
    Solberg LI, Parker ED, Foldes SS, et al. Disparities in tobacco cessation medication orders and fills among special populations. Nicotine Tob Res 2010 Feb; 12(2): 144–51PubMedCrossRefGoogle Scholar
  92. 92.
    Robles GI, Singh-Franco D, Ghin HL. A review of the efficacy of smoking-cessation pharmacotherapies in non-white populations. Clin Ther 2008 May; 30(5): 800–12PubMedCrossRefGoogle Scholar
  93. 93.
    Baha MY, Le Faou AL. Smoking cessation interventions offered to French adult light smokers: a heterogeneous population with specific needs. Eur Addict Res 2010 May 7; 16(3): 162–9PubMedCrossRefGoogle Scholar
  94. 94.
    Oncken CA, Kranzler HR. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res 2009 Nov; 11(11): 1265–73PubMedCrossRefGoogle Scholar
  95. 95.
    Ussher M, Aveyard P, Coleman T, et al. Physical activity as an aid to smoking cessation during pregnancy: two feasibility studies. BMC Public Health 2008; 8: 328PubMedCrossRefGoogle Scholar
  96. 96.
    Swan GE, Jack LM, Curry S, et al. Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome. Nicotine Tob Res 2003 Dec; 5(6): 911–21PubMedCrossRefGoogle Scholar
  97. 97.
    Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol 2004 Aug; 72(4): 712–22PubMedCrossRefGoogle Scholar
  98. 98.
    Burgess DJ, Fu SS, Noorbaloochi S, et al. Employment, gender, and smoking cessation outcomes in low-income smokers using nicotine replacement therapy. Nicotine Tob Res 2009 Dec; 11(12): 1439–47PubMedCrossRefGoogle Scholar
  99. 99.
    Kotz D, West R. Explaining the social gradient in smoking cessation: it’s not in the trying, but in the succeeding. Tob Control 2009 Feb; 18(1): 43–6PubMedCrossRefGoogle Scholar
  100. 100.
    Jha P, Peto R, Zatonski W, et al. Social inequalities in male mortality, and in male mortality from smoking: indirect estimation from national death rates in England and Wales, Poland, and North America. Lancet 2006 Jul 29; 368(9533): 367–70PubMedCrossRefGoogle Scholar
  101. 101.
    Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296(1): 47–55PubMedCrossRefGoogle Scholar
  102. 102.
    Etter JF, Stapleton J. Citations to trials of nicotine replacement therapy were biased toward positive results and high-impact-factor journals. J Clin Epidemiol 2009 Aug; 62(8): 831–7PubMedCrossRefGoogle Scholar
  103. 103.
    Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev 2008 Sep; 27(5): 529–47PubMedCrossRefGoogle Scholar
  104. 104.
    McEwen A, West R. Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services. BMC Public Health 2009; 9: 28PubMedCrossRefGoogle Scholar
  105. 105.
    Grassi MC, Enea D, Ferketich AK, et al. A smoking ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year. Nicotine Tob Res 2009 Sep; 11(9): 1114–21PubMedCrossRefGoogle Scholar
  106. 106.
    Krist AH, Woolf SH, Johnson RE, et al. Patient costs as a barrier to intensive health behavior counseling. Am J Prev Med 2010 Mar; 38(3): 344–8PubMedCrossRefGoogle Scholar
  107. 107.
    Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med 2010; 7(2): e1000216PubMedCrossRefGoogle Scholar
  108. 108.
    Fiore MC, Novotny TE, Pierce JP, et al. Methods used to quit smoking in the United States: do cessation programs help? JAMA 1990 May 23–30; 263(20): 2760–5PubMedCrossRefGoogle Scholar
  109. 109.
    West R, Sohal T. ‘Catastrophic’ pathways to smokingcessation: findings from national survey. BMJ 2006 Feb 25; 332(7539): 458–60PubMedCrossRefGoogle Scholar
  110. 110.
    Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control 2006 Jun; 15(3): 152–9PubMedCrossRefGoogle Scholar
  111. 111.
    Annemans L, Nackaerts K, Bartsch P, et al. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig 2009; 29(10): 655–65PubMedCrossRefGoogle Scholar
  112. 112.
    Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008 Jan; 24(1): 51–61PubMedGoogle Scholar
  113. 113.
    Linden K, Jormanainen V, Linna M, et al. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin 2010 Mar; 26(3): 549–60PubMedCrossRefGoogle Scholar
  114. 114.
    Vemer P, Rutten-van Molken MP. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010 Mar–Apr; 13(2): 230–41PubMedCrossRefGoogle Scholar
  115. 115.
    Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains: in our lifetime. Am J Prev Med 2007 Dec; 33(6 Suppl. ): S340–8PubMedCrossRefGoogle Scholar
  116. 116.
    Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men? Clin Chest Med 2004 Jun; 25(2): 331–41PubMedCrossRefGoogle Scholar
  117. 117.
    Henschke CI, Miettinen OS. Women’s susceptibility to tobacco carcinogens. Lung Cancer 2004 Jan; 43(1): 1–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Department of Cardiology and PneumologyUniversity Hospital GöttingenGöttingenGermany
  2. 2.Department of General PracticeCare and Public Health Research Institute (CAPHRI), Maastricht UniversityMaastrichtthe Netherlands

Personalised recommendations